Esperion Therapeutics, Inc. provided earnings guidance for the fourth quarter of 2021. For the fourth quarter of 2021 net U.S. product sales are expected to be between $12.0 to $12.5 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.08 USD | +0.97% | +9.47% | -30.43% |
25/03 | Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol | DJ |
25/03 | Sector Update: Health Care Stocks Steady Premarket Monday | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.43% | 394M | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- ESPR Stock
- News Esperion Therapeutics, Inc.
- Esperion Therapeutics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2021